



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL - 6 2006

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Office of Regulatory Policy  
HFD - 13  
5600 Fishers Lane,  
Rockville, MD 20857

Attention: Beverly Friedman


Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 6,001,876. The application was filed on February 25, 2005, under 35 U.S.C. § 156. It is noted that the patent term extension application for U.S. Patent No. 6,001,876 is based on NDA No. 21-734.

Another patent term extension application for U.S. Patent No. 6,197,819 has been filed on the approved product Lyrica® relating to NDA No. 21-446.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to Mary C. Till at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

  
Kery A. Fries  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Karen DeBenedictis  
Warner-Lambert Company LLC  
2800 Plymouth Road, 016/410E/PAT/6  
Ann Arbor, MI 48105

RE: Lyrica® (pregabalin)  
FDA Docket No. 2006E-0005